Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Januzzi JL Jr, et al. Among authors: snapinn sm. Circulation. 2002 May 21;105(20):2361-6. doi: 10.1161/01.cir.0000016359.94919.16. Circulation. 2002. PMID: 12021221 Clinical Trial.
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ, Théroux P, Snapinn SM, Sax FL. Zhao XQ, et al. Among authors: snapinn sm. Circulation. 1999 Oct 12;100(15):1609-15. doi: 10.1161/01.cir.100.15.1609. Circulation. 1999. PMID: 10517731 Clinical Trial.
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P, Alexander J Jr, Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL. Théroux P, et al. Circulation. 2000 Nov 14;102(20):2466-72. doi: 10.1161/01.cir.102.20.2466. Circulation. 2000. PMID: 11076818 Clinical Trial.
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Blazing MA, et al. Among authors: snapinn sm. JAMA. 2004 Jul 7;292(1):55-64. doi: 10.1001/jama.292.1.55. JAMA. 2004. PMID: 15238591 Clinical Trial.
96 results